infigratinib
AssetAlso BGJ-398, MVP-BGJ398, NVP-BGJ398
Inhibits FGFR tyrosine kinases, reducing excessive FGFR3 signaling that impairs bone growth in achondroplasia.
- Stage
- Approved
- Modality
- Small molecule
- Target
- FGFR1
- 3
- Indications
- 2
- Trials
- 1
- Developer
Indications
4No named disease
Approved, open.fda.gov, May 28, 2021
Advanced cholangiocarcinoma
Phase 3, Terminated, NCT03773302, clinicaltrials.gov, Oct 31, 2026
Fgfr2 gene mutation
Phase 3, Terminated, NCT03773302, clinicaltrials.gov, Oct 31, 2026
1 more
In the full profile
- Targets and what it contains4
- Owner and partners1
- Trials2
- Evidence for its targets5
- Competitors8
- Signals4
Every asset’s record: target, stage, trials and the evidence behind it.